NASDAQ:QDEL

QuidelOrtho (QDEL) Stock Price, News & Analysis

$40.40
+1.32 (+3.38%)
(As of 04/23/2024 ET)
Today's Range
$38.98
$40.82
50-Day Range
$38.26
$66.77
52-Week Range
$37.78
$95.02
Volume
1.19 million shs
Average Volume
1.01 million shs
Market Capitalization
$2.70 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$61.60

QuidelOrtho MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
52.5% Upside
$61.60 Price Target
Short Interest
Healthy
3.36% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
0.18mentions of QuidelOrtho in the last 14 days
Based on 28 Articles This Week
Insider Trading
Acquiring Shares
$99,652 Bought Last Quarter
Proj. Earnings Growth
74.56%
From $2.28 to $3.98 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.95 out of 5 stars

Medical Sector

14th out of 910 stocks

Diagnostic Substances Industry

1st out of 11 stocks

QDEL stock logo

About QuidelOrtho Stock (NASDAQ:QDEL)

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.

QDEL Stock Price History

QDEL Stock News Headlines

QDEL May 2024 50.000 call
QDEL May 2024 40.000 put
Exposed: 10 CENT Crypto to Explode April 20th?
Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin
Exposed: 10 CENT Crypto to Explode April 20th?
Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin
See More Headlines
Receive QDEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for QuidelOrtho and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/13/2024
Today
4/23/2024
Next Earnings (Confirmed)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Health Care Supplies
Current Symbol
NASDAQ:QDEL
CUSIP
74838J10
Employees
7,100
Year Founded
1979

Price Target and Rating

Average Stock Price Target
$61.60
High Stock Price Target
$81.00
Low Stock Price Target
$37.00
Potential Upside/Downside
+52.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
7 Analysts

Profitability

Net Income
$-10,100,000.00
Pretax Margin
-0.97%

Debt

Sales & Book Value

Annual Sales
$3.00 billion
Cash Flow
$11.35 per share
Book Value
$74.92 per share

Miscellaneous

Free Float
66,210,000
Market Cap
$2.70 billion
Optionable
Optionable
Beta
0.11

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Michael S. Iskra (Age 54)
    Interim CEO, Executive VP & Chief Commercial Officer
    Comp: $870.93k
  • Mr. Robert J. Bujarski J.D. (Age 55)
    Interim President, Executive VP & COO
    Comp: $961.26k
  • Mr. Joseph M. Busky CPA (Age 56)
    Chief Financial Officer
    Comp: $890.63k
  • Dr. Werner Kroll Ph.D. (Age 67)
    Senior Vice President of Research & Development
    Comp: $1.03M
  • Ms. Louise M. Brandy (Age 65)
    Chief Information Officer
  • Ruben Argueta
    Director of Investor Relations
  • Ms. Michelle A. Hodges J.D. (Age 61)
    Senior VP, General Counsel & Corporate Secretary
    Comp: $1.8M
  • Mr. William J. FerenczyMr. William J. Ferenczy (Age 68)
    Point of Care Business Unit Leader
  • Ms. Tamara A. Ranalli (Age 51)
    Molecular Diagnostics Business Unit Leader

QDEL Stock Analysis - Frequently Asked Questions

Should I buy or sell QuidelOrtho stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for QuidelOrtho in the last year. There are currently 2 sell ratings, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" QDEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QDEL, but not buy additional shares or sell existing shares.
View QDEL analyst ratings
or view top-rated stocks.

What is QuidelOrtho's stock price target for 2024?

7 brokers have issued 12 month price targets for QuidelOrtho's shares. Their QDEL share price targets range from $37.00 to $81.00. On average, they expect the company's stock price to reach $61.60 in the next year. This suggests a possible upside of 52.5% from the stock's current price.
View analysts price targets for QDEL
or view top-rated stocks among Wall Street analysts.

How have QDEL shares performed in 2024?

QuidelOrtho's stock was trading at $73.70 on January 1st, 2024. Since then, QDEL stock has decreased by 45.2% and is now trading at $40.40.
View the best growth stocks for 2024 here
.

When is QuidelOrtho's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our QDEL earnings forecast
.

How can I listen to QuidelOrtho's earnings call?

QuidelOrtho will be holding an earnings conference call on Wednesday, May 8th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were QuidelOrtho's earnings last quarter?

QuidelOrtho Co. (NASDAQ:QDEL) released its earnings results on Tuesday, February, 13th. The company reported $1.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.01 by $0.84. The business had revenue of $742.60 million for the quarter, compared to the consensus estimate of $796.91 million. QuidelOrtho had a negative net margin of 0.34% and a positive trailing twelve-month return on equity of 5.54%. The business's revenue for the quarter was down 14.3% on a year-over-year basis. During the same period in the previous year, the business posted $1.74 EPS.

What guidance has QuidelOrtho issued on next quarter's earnings?

QuidelOrtho updated its FY 2024 earnings guidance on Tuesday, February, 13th. The company provided EPS guidance of 2.400-3.070 for the period, compared to the consensus estimate of 5.070. The company issued revenue guidance of $2.8 billion-$3.1 billion, compared to the consensus revenue estimate of $3.0 billion.

What is Doug Bryant's approval rating as QuidelOrtho's CEO?

47 employees have rated QuidelOrtho Chief Executive Officer Doug Bryant on Glassdoor.com. Doug Bryant has an approval rating of 76% among the company's employees.

What other stocks do shareholders of QuidelOrtho own?

Based on aggregate information from My MarketBeat watchlists, some companies that other QuidelOrtho investors own include NVIDIA (NVDA), DocuSign (DOCU), Tesla (TSLA), PayPal (PYPL), Shopify (SHOP), Block (SQ), Teladoc Health (TDOC), Netflix (NFLX), Advanced Micro Devices (AMD) and Zoom Video Communications (ZM).

Who are QuidelOrtho's major shareholders?

QuidelOrtho's stock is owned by a number of institutional and retail investors. Top institutional investors include Leeward Investments LLC MA (0.33%), Allspring Global Investments Holdings LLC (0.11%), Amalgamated Bank (0.05%), Hunter Perkins Capital Management LLC (0.02%), State of Michigan Retirement System (0.02%) and Oak Thistle LLC (0.01%). Insiders that own company stock include Charles P Slacik, Joseph M Busky, Mary Lake Ph D Polan and William J Ferenczy.
View institutional ownership trends
.

How do I buy shares of QuidelOrtho?

Shares of QDEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:QDEL) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners